TY - JOUR
T1 - The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable
AU - Knopman, David S.
AU - Haeberlein, Samantha Budd
AU - Carrillo, Maria C.
AU - Hendrix, James A.
AU - Kerchner, Geoff
AU - Margolin, Richard
AU - Maruff, Paul
AU - Miller, David S.
AU - Tong, Gary
AU - Tome, Maria B.
AU - Murray, Melissa E.
AU - Nelson, Peter T.
AU - Sano, Mary
AU - Mattsson, Niklas
AU - Sultzer, David L.
AU - Montine, Thomas J.
AU - Jack, Clifford R.
AU - Kolb, Hartmuth
AU - Petersen, Ronald C.
AU - Vemuri, Prashanthi
AU - Canniere, Megan Zoschg
AU - Schneider, Julie A.
AU - Resnick, Susan M.
AU - Romano, Gary
AU - van Harten, Argonde Corien
AU - Wolk, David A.
AU - Bain, Lisa J.
AU - Siemers, Eric
PY - 2018
Y1 - 2018
N2 - The Alzheimer's Association's Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease. The meeting allowed experts in the field from academia, industry, and government to provide perspectives on the new National Institute on Aging and the Alzheimer's Association Research Framework. This review will summarize the “A, T, N System” (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be applied to clinical research and drug development. In addition, challenges and barriers to the potential adoption of this new framework will be discussed. Finally, future directions for research will be proposed.
AB - The Alzheimer's Association's Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease. The meeting allowed experts in the field from academia, industry, and government to provide perspectives on the new National Institute on Aging and the Alzheimer's Association Research Framework. This review will summarize the “A, T, N System” (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be applied to clinical research and drug development. In addition, challenges and barriers to the potential adoption of this new framework will be discussed. Finally, future directions for research will be proposed.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044929982&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29653607
U2 - 10.1016/j.jalz.2018.03.002
DO - 10.1016/j.jalz.2018.03.002
M3 - Article
C2 - 29653607
VL - 14
SP - 563
EP - 575
JO - Alzheimers & Dementia
JF - Alzheimers & Dementia
SN - 1552-5260
IS - 4
ER -